$250.75
0.270.11%
Dern. MÀJ: Nov 13, 11:56 AM
Biogen rose 52.1% from $164.73 to $250.48, ahead of the S&P 500's +12.7%. Its worst day was Jul 14 (−8.2%), and its low came Jan 16 at $164.42.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Biogen closed at its lowest level of the year, 0.2% below where the year started.
−2.5% · S&P 500 −0.1%
EPS of $1.99 beat the $1.62 estimate on $2.3B revenue (est. $2.2B); FY EPS guidance of $15.25–$16.25 against the $14.94 consensus.
Story events cover the past 12 months · Times ET
+8.5%, the year's best day · S&P 500 +1.9%
EPS of $3.57 beat the $2.95 estimate on $2.5B revenue (est. $2.2B); FY EPS guidance of $15.25–$16.25 against the $13.45 consensus.
+6.0% · S&P 500 0.0%
Biogen shares fell 6.4%, while the S&P 500 rose 0.8%.
−6.4% · S&P 500 +0.8%
Biogen shares rose 7.0%, while the S&P 500 fell 0.7%.
+7.0% · S&P 500 −0.7%
TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.
−8.2%, the year's worst day · S&P 500 +0.4%
EPS of $3.60 beat the $2.35 estimate on $2.7B revenue (est. $2.4B); FY EPS guidance of $15.85–$16.85 against the $13.45 consensus.
+1.8% · S&P 500 −1.5%
EPS of $2.62 beat the $1.99 estimate on $2.8B revenue (est. $2.6B); FY EPS guidance of $15.95–$16.75 against the $12.35 consensus.
−3.4% · S&P 500 +0.3%
Biogen closed at its highest level of the year, 54.7% above where the year started.
+2.6% · S&P 500 +2.4%
Where it ended: a close of $250.48 on Nov 12, 2026. Up next: Q4 2026 earnings on Feb 5, 2027 (EPS est. $2.80, revenue est. $2.6B).
Nothing in the past 12 months.
All BIIB dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BIIB and SPY from Benzinga historical bars. Not investment advice.